HER2 inhibitors extend survival in HER2-amplified breast cancers; however, they are not sufficiently active as monotherapy1,2, unlike other receptor tyrosine kinase (RTK) inhibitors in solid tumor cancer paradigms. The gene discussed is ERBB2; the disease is breast cancer.